Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Neogen (NEOG) Stock Trades Down, Here Is Why

July 29, 2025 at 14:25 PM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

NEOG Cover Image

What Happened?

Shares of life sciences company Neogen (NASDAQ: NEOG) fell 10.2% in the morning session after the company reported disappointing fourth-quarter financial results, which showed a decline in revenue and adjusted earnings that fell short of analyst expectations. The food and animal safety company announced that revenue for the quarter ended May 31, 2025, decreased by 4.8% to $225.5 million compared to the prior year. Neogen also posted a significant net loss of $612.2 million, which it attributed mainly to a non-cash goodwill impairment charge related to its acquisition of the former 3M Food Safety Division. On an adjusted basis, net income was $0.05 per share, a drop from $0.10 in the same period last year and below Wall Street's consensus estimates. Management cited softer market conditions and the effects of inflation as key factors behind the weak performance.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Neogen? Access our full analysis report here, it’s free.

What Is The Market Telling Us

Neogen’s shares are extremely volatile and have had 37 moves greater than 5% over the last year. But moves this big are rare even for Neogen and indicate this news significantly impacted the market’s perception of the business.

The previous big move we wrote about was 5 days ago when the stock gained 3.4% on the news that the company announced the appointment of Mike Nassif as its new Chief Executive Officer and President. Nassif was set to take the helm on August 11, 2025, succeeding John Adent. The incoming CEO previously served as the Global President of the Point-of-Care Diagnostics business at Siemens Healthineers. During his tenure there, he was instrumental in driving significant growth. This leadership change appeared to resonate positively with investors, who likely viewed Nassif's track record as a strong indicator of his potential to guide Neogen's future operational direction and market position.

Neogen is down 59.3% since the beginning of the year, and at $4.86 per share, it is trading 72.3% below its 52-week high of $17.58 from July 2024. Investors who bought $1,000 worth of Neogen’s shares 5 years ago would now be looking at an investment worth $128.62.

Do you want to know what moves the business you care about? Add them to your StockStory watchlist and every time a stock significantly moves, we provide you with a timely explanation straight to your inbox. It’s free and will only take you a second.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article